Open Orphan Shares Edged Higher After Appointing a New CFO

Key points:
Open Orphan shares edged higher after the appointment of a new CFO.
Investors reacted well to the news, but the price did not rise much.
OPRH shares have been falling, but the company is rebranding to hVIVO Plc.

The Open Orphan PLC (LON: ORPH) share price edged higher after Stephen Pinkerton’s appointment as its new Chief Financial Officer (CFO) to replace Leo Toole, who has stepped down from the board and his role as CFO.

The company noted that Stephen has been with the company for six years and started as a consultant before joining the company full-time in July 2017 as the Commercial Financial director of hVIVO, the high-flying subsidiary.

Also read: The Best Healthcare Stocks To Buy Right Now.

X testing X

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Stephen had multiple senior financial roles spanning over 11 years at Thomson Reuters before joining hVIVO. He will be based at Open Orphan’s Plumbers Row headquarters in East London and will work alongside the Company’s CEO, Yamin’ Mo’ Khan.

Open Orphan is also rebranding into hVIVO following the subsidiary’s successful human challenge trials that have transformed it into a global powerhouse in designing and executing human challenge trials.

The name Open Orphan is likely obscuring hVIVO immense success, and the renaming of the firm into hVIVO Plc on 26 October 2022 will align the company with its most successful business unit.

Furthermore, the company noted that its Executive Chairman Cathal Friel would be retreating from its daily operations by taking on the less-involved role of Non-Executive Chairman. Cathal expressed confidence that since his appointment as CEO on 24 February 2022, Yamin’ Mo’ Khan has proven that he is more capable of running the company.

Open Orphan’s future looks promising as the company continues to win multiple contracts to conduct human challenge trials for global pharmaceutical and healthcare companies. However, ORPH shares have not performed well this year and are down 56.7% YTD.

The company’s shares seem to be forming a bottoming pattern, but it is too early to tell. Therefore, I would wait for a robust confirmation of an uptrend before buying ORPH shares.

*This is not investment advice.

Open Orphan share price.

The Open Orphan share price edged higher after the appointment of a new CFO.